Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Point Therapeutics |
---|---|
Information provided by: | Point Therapeutics |
ClinicalTrials.gov Identifier: | NCT00083252 |
The purpose of this study is to assess the antitumor activity and safety of the combination of talabostat and cisplatin in patients with metastatic melanoma.
Condition | Intervention | Phase |
---|---|---|
Melanoma Skin Cancer |
Drug: talabostat (PT-100) tablets Drug: cisplatin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arkansas | |
University of Arkansas Medical Sciences | |
Little Rock, Arkansas, United States, 72205 | |
United States, California | |
Cancer Institute Medical Group, Inc. | |
Santa Monica, California, United States, 90404 | |
United States, Colorado | |
University of Colorado Health Sciences Center | |
Aurora, Colorado, United States, 80045 | |
United States, Florida | |
Cancer Center of Florida | |
Ocoee, Florida, United States, 34761 | |
United States, Indiana | |
Indiana Hematology Oncology Consultants | |
Indianapolis, Indiana, United States, 46202 | |
United States, New Mexico | |
New Mexico Cancer Center Alliance | |
Albuquerque, New Mexico, United States, 87106 | |
United States, New York | |
NYU School of Medicine | |
New York, New York, United States, 10016 | |
Fifth Avenue Medical Healthcare | |
New York, New York, United States, 10128 | |
United States, North Carolina | |
Carolinas Medical Center | |
Charlotte, North Carolina, United States, 28203 | |
United States, South Carolina | |
Cancer Center of the Carolinas | |
Greenville, South Carolina, United States, 29615 | |
United States, Texas | |
Mary Crowley Medical Research Center | |
Dallas, Texas, United States, 75246 | |
Tyler Cancer Center | |
Tyler, Texas, United States, 75702 | |
United States, Washington | |
Cancer Care Northwest Research | |
Spokane, Washington, United States, 99218 |
Study ID Numbers: | PTH-303 |
Study First Received: | May 14, 2004 |
Last Updated: | June 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00083252 |
Health Authority: | United States: Food and Drug Administration |
Neuroectodermal Tumors Cisplatin Skin Diseases Nevus, Pigmented Neoplasms, Germ Cell and Embryonal |
Neuroepithelioma Nevus Skin Neoplasms Neuroendocrine Tumors Melanoma |
Neoplasms Neoplasms by Histologic Type Neoplasms by Site Radiation-Sensitizing Agents Antineoplastic Agents |
Therapeutic Uses Physiological Effects of Drugs Neoplasms, Nerve Tissue Nevi and Melanomas Pharmacologic Actions |